Hence, an increase in the percentage of persons treated with “Insulin and non-insulin GLD” might reflect an increase in persons with type 2 diabetes not reaching treatment goals (in general, HbA1c > 53.0 mmol/mol (7%)) with non-insulin GLD only. This evidence concerns the gene INS and type 2 diabetes mellitus.